Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC).

Wald O.

J Clin Med. 2018 Sep 25;7(10). pii: E303. doi: 10.3390/jcm7100303. Review.

2.

Matrix metalloproteinase 12 promotes tumor propagation in the lung.

Ella E, Harel Y, Abraham M, Wald H, Benny O, Karsch-Bluman A, Vincent D, Laurent D, Amir G, Izhar U, Shapira OM, Yoon D, Lee HS, Sugarbaker DJ, Burt B, Peled A, Wald O.

J Thorac Cardiovasc Surg. 2018 May;155(5):2164-2175.e1. doi: 10.1016/j.jtcvs.2017.11.110. Epub 2018 Feb 21.

PMID:
29429629
3.

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.

Klein S, Abraham M, Bulvik B, Dery E, Weiss ID, Barashi N, Abramovitch R, Wald H, Harel Y, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Pereg Y, Peled A.

Cancer Res. 2018 Mar 15;78(6):1471-1483. doi: 10.1158/0008-5472.CAN-17-0454. Epub 2017 Dec 19.

PMID:
29259008
4.

New Concepts in the Treatment of Malignant Pleural Mesothelioma.

Wald O, Sugarbaker DJ.

Annu Rev Med. 2018 Jan 29;69:365-377. doi: 10.1146/annurev-med-041316-085813. Epub 2017 Oct 13.

PMID:
29029582
5.

Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient.

Wald O, Sugarbaker DJ.

J Thorac Dis. 2017 Mar;9(3):485-489. doi: 10.21037/jtd.2017.03.27. No abstract available.

6.

Future directions in esophageal cancer therapy.

Wald O, Smaglo B, Mok H, Groth SS.

Ann Cardiothorac Surg. 2017 Mar;6(2):159-166. doi: 10.21037/acs.2017.02.01.

7.

High mobility group box 1 antagonist limits metastatic seeding in the lungs via reduction of cell-cell adhesion.

Karsch-Bluman A, Amoyav B, Friedman N, Shoval H, Schwob O, Ella E, Wald O, Benny O.

Oncotarget. 2017 May 16;8(20):32706-32721. doi: 10.18632/oncotarget.16188.

8.

Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.

Lee HS, Jang HJ, Shah R, Yoon D, Hamaji M, Wald O, Lee JS, Sugarbaker DJ, Burt BM.

Clin Cancer Res. 2017 Aug 15;23(16):4855-4864. doi: 10.1158/1078-0432.CCR-17-0066. Epub 2017 Apr 11.

9.

Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.

Wald O, Groth SS, Burt BM, Sugarbaker DJ.

J Vis Surg. 2016 Aug 2;2:129. doi: 10.21037/jovs.2016.07.12. eCollection 2016. Review.

10.

Pneumonectomy for Non-Small Cell Lung Cancer.

Sugarbaker DJ, Haywood-Watson RJ, Wald O.

Surg Oncol Clin N Am. 2016 Jul;25(3):533-51. doi: 10.1016/j.soc.2016.02.012. Review.

PMID:
27261914
11.

Perspective on malignant pleural mesothelioma diagnosis and treatment.

Wald O, Sugarbaker DJ.

Ann Transl Med. 2016 Mar;4(6):120. doi: 10.21037/atm.2016.03.17. No abstract available.

12.

In the hunt for therapeutic targets: mimicking the growth, metastasis, and stromal associations of early-stage lung cancer using a novel orthotopic animal model.

Weiss ID, Ella E, Dominsky O, Smith Y, Abraham M, Wald H, Shlomai Z, Zamir G, Feigelson SW, Shezen E, Bar-Shai A, Alon R, Izhar U, Peled A, Shapira OM, Wald O.

J Thorac Oncol. 2015 Jan;10(1):46-58. doi: 10.1097/JTO.0000000000000367.

13.

Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.

Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A.

Mol Cancer Ther. 2014 May;13(5):1155-69. doi: 10.1158/1535-7163.MCT-13-0410. Epub 2014 Feb 6.

14.

Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.

Abraham M, Weiss ID, Wald H, Wald O, Nagler A, Beider K, Eizenberg O, Peled A.

Br J Haematol. 2013 Oct;163(2):248-59. doi: 10.1111/bjh.12501. Epub 2013 Aug 1.

PMID:
23906028
15.

Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice.

Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E, Abramovitch R, Zeira E, Galun E, Peled A.

Hepatology. 2013 Sep;58(3):1021-30. doi: 10.1002/hep.26403. Epub 2013 Jul 12.

PMID:
23526353
16.

Radical multidisciplinary approach to primary cardiac sarcomas.

Shapira OM, Korach A, Izhar U, Koler T, Wald O, Ayman M, Erez E, Blackmon SH, Reardon MJ.

Eur J Cardiothorac Surg. 2013 Aug;44(2):330-5; discussion 335-6. doi: 10.1093/ejcts/ezt029. Epub 2013 Feb 7.

PMID:
23392107
17.

CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.

Wald O, Shapira OM, Izhar U.

Theranostics. 2013;3(1):26-33. doi: 10.7150/thno.4922. Epub 2013 Jan 13. Review.

18.

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.

Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O.

J Thorac Cardiovasc Surg. 2012 Nov;144(5):1167-1175.e1. doi: 10.1016/j.jtcvs.2012.07.031. Epub 2012 Aug 24.

19.

Development of novel CXCR4-based therapeutics.

Peled A, Wald O, Burger J.

Expert Opin Investig Drugs. 2012 Mar;21(3):341-53. doi: 10.1517/13543784.2012.656197. Epub 2012 Jan 28. Review.

PMID:
22283809
20.

Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O.

PLoS One. 2011;6(9):e24856. doi: 10.1371/journal.pone.0024856. Epub 2011 Sep 15.

Supplemental Content

Loading ...
Support Center